Incannex Healthcare Inc
For the period ended Sep 30, 2024. Filed Nov 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 14, 2024
IXHL$2.01-8.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| For the three months ended September 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net loss | $(5,420) | $(726) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 64 | 12 |
| Share-based compensation expense | 459 | 201 |
| Repayment of lease liabilities | 52 | (25) |
| Unrealized loss on foreign currency remeasurement | 5 | 2 |
| Change in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 177 | (601) |
| R&D tax incentive | (839) | (3,975) |
| Trade and other payables | 1,067 | (250) |
| Accrued expenses and other current liabilities | 2,242 | (387) |
| Net cash used in operating activities | (2,193) | (5,749) |
| Cash flows from investing activities: | ||
| Purchase of property, plant and equipment | - | (221) |
| Net cash used in investing activities | - | (221) |
| Cash flows from financing activities: | ||
| Repayment of lease liabilities | (52) | - |
| Net cash provided by financing activities | (52) | - |
| Effect of exchange rate changes on cash and cash equivalents | 14 | 128 |
| Net decrease in cash and cash equivalents | (2,231) | (5,842) |
| Cash and cash equivalents at beginning of period | 5,858 | 22,120 |
| Cash and cash equivalents at end of period | $3,627 | $16,278 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.